- Public Comps
- Vivos
Vivos Valuation Multiples
Discover Vivos' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Myomo, Ortoma, Elutia, Optomed and more.
Vivos Overview
About Vivos
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Founded
1994
HQ

Employees
1
Website
Financials (FY)
EV
$42M
Valuation Multiples
Start free trialVivos Financials
Vivos reported last fiscal year revenue of $68K and negative EBITDA of ($3M).
In the same fiscal year, Vivos generated ($60K) in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).
Vivos P&L
In the most recent fiscal year, Vivos reported revenue of $68K and EBITDA of ($3M).
Vivos is unprofitable as of last fiscal year, with gross margin of (87%), EBITDA margin of (4628%), and net margin of (4484%).
Financial data powered by Morningstar, Inc.
Vivos Stock Performance
Vivos has current market cap of $44M, and enterprise value of $42M.
Market Cap Evolution
Vivos' stock price is $0.09.
Vivos share price increased by 47.0% in the last 30 days, and decreased by 23.4% in the last year.
Vivos has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42M | $44M | 4.9% | 47.0% | 30.2% | -23.4% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVivos Valuation Multiples
Vivos trades at 614.8x EV/Revenue multiple, and (13.3x) EV/EBITDA.
Vivos Financial Valuation Multiples
As of July 8, 2026, Vivos has market cap of $44M and EV of $42M.
Vivos has a P/E ratio of (14.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vivos Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Vivos Margins & Growth Rates
In the most recent fiscal year, Vivos reported gross margin of (87%), EBITDA margin of (4628%), and net margin of (4484%).
Vivos Margins
Vivos Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Vivos Operational KPIs
Vivos' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $3.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Vivos Competitors
Vivos competitors include Myomo, Ortoma, Elutia, Optomed, OssDsign, RenovoRx, Episurf Medical, Singular Health, Baumer and Biohit.
Most Vivos public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.2x | 1.1x | (4.2x) | (4.6x) | |||
| 5.9x | 6.1x | (94.2x) | (24.7x) | |||
| 1.5x | 1.5x | (1.4x) | (1.3x) | |||
| 1.8x | 1.8x | (8.8x) | (13.8x) | |||
| 1.4x | 1.6x | (7.0x) | (6.3x) | |||
| 26.6x | 13.6x | (2.4x) | - | |||
| 32.8x | - | (9.0x) | - | |||
| 280.9x | - | (9.3x) | - | |||
This data is available for Pro users. Sign up to see all Vivos competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Vivos
Vivos has acquired 1 company to date.
Last acquisition by Vivos was on July 15th 2025. Vivos acquired Nice-Pak Products for undisclosed valuation.
Latest Acquisitions by Vivos
| Description | Nice-Pak Products is a New Hyde Park-headquartered manufacturer of wet wipes, including sanitizing, baby, flushable, and surface disinfectant varieties produced in facilities across the United States, United Kingdom, and Mexico. Founded in 1960, it supplies private-label products to retailers like Walmart and Procter & Gamble, with production capacity exceeding billions of wipes annually using biodegradable materials. |
| HQ Country | |
| HQ City | New York City, NY |
| Deal Date | 15 Jul 2025 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Vivos acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vivos
| When was Vivos founded? | Vivos was founded in 1994. |
| Where is Vivos headquartered? | Vivos is headquartered in United States. |
| How many employees does Vivos have? | As of today, Vivos has over 1 employees. |
| Is Vivos publicly listed? | Yes, Vivos is a public company listed on OTCM. |
| What is the stock symbol of Vivos? | Vivos trades under RDGL ticker. |
| Who are competitors of Vivos? | Vivos main competitors include Myomo, Ortoma, Elutia, Optomed, OssDsign, RenovoRx, Episurf Medical, Singular Health, Baumer, Biohit. |
| What is the current market cap of Vivos? | Vivos' current market cap is $44M. |
| What is the current revenue of Vivos? | Vivos' last fiscal year revenue is $68K. |
| What is the current EV/Revenue multiple of Vivos? | Current revenue multiple of Vivos is 614.8x. |
| Is Vivos profitable? | No, Vivos is not profitable. |
| How many companies Vivos has acquired to date? | As of July 2026, Vivos has acquired 1 company. |
| What was the largest acquisition by Vivos? | None of the M&A deals Vivos has completed have disclosed valuations. |
| In how many companies Vivos has invested to date? | Vivos hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Vivos
Lists including Vivos
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





